{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:33:13Z","timestamp":1773145993214,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1124\/dmd.30.4.452","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:17:35Z","timestamp":1042672655000},"page":"452-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211"],"prefix":"10.1016","volume":"30","author":[{"given":"Stephen M.","family":"Fowler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.Roland","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.30.4.452_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0014-5793(96)01196-9","article-title":"Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli.","volume":"397","author":"Blake","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1124\/dmd.30.4.452_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450.","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.452_bib3","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.452_bib4","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1021\/bi992372u","article-title":"Amino acid 305 determines catalytic center accessibility in CYP3A4.","volume":"39","author":"Fowler","year":"2000","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.30.4.452_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03190959","article-title":"Synthetic strategies to lower affinity for CYP2D6.","volume":"22","author":"Halliday","year":"1997","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.30.4.452_bib6","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1074\/jbc.272.9.5396","article-title":"Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity.","volume":"272","author":"Harlow","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.30.4.452_bib7","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1073\/pnas.95.12.6636","article-title":"Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics.","volume":"95","author":"Harlow","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.30.4.452_bib8","first-page":"282","article-title":"A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.","volume":"29","author":"Ishigami","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.452_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/abbi.1999.1578","article-title":"Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes.","volume":"373","author":"Khan","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.4.452_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/clpt.1988.87","article-title":"Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.","volume":"43","author":"Kronbach","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.30.4.452_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1073\/pnas.82.2.488","article-title":"Rapid and efficient site-specific mutagenesis without phenotypic selection.","volume":"82","author":"Kunkel","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.30.4.452_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0165-6147(93)90080-4","article-title":"Further concerns over Cheng-Prusoff analysis.","volume":"14","author":"Leff","year":"1993","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.30.4.452_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00008571-199802000-00005","article-title":"Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.","volume":"8","author":"Pritchard","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.4.452_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/abbi.1997.0265","article-title":"A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1.","volume":"345","author":"Pritchard","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.4.452_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1023\/A:1011085411050","article-title":"Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery.","volume":"18","author":"Riley","year":"2001","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.30.4.452_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1007956612081","article-title":"Molecular modeling of cytochrome P450 3A4.","volume":"11","author":"Szklarz","year":"1997","journal-title":"J Comput-Aided Mol Des"},{"key":"10.1124\/dmd.30.4.452_bib17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0006-291X(74)90341-6","article-title":"Highly purified detergent-solubilized NADPH-cytochrome P-450 reductase from phenobarbital-induced rat liver microsomes.","volume":"60","author":"Vermilion","year":"1974","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.30.4.452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:13:31Z","timestamp":1739902411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624044209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0090955624044209"],"URL":"https:\/\/doi.org\/10.1124\/dmd.30.4.452","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.30.4.452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}